Nicolas Charloteaux - 29 Sep 2020
Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic. Johnson & Johnson has mobilised resources in response to the outbreak to develop a preventive vaccine candidate against this coronavirus, leveraging Janssen’s AdVac® and PER.C6® technology, that provide the ability to rapidly upscale production of the optimal vaccine candidate. These are the same technologies that are used in the development and manufacturing of Janssen’s investigational Ebola vaccine and are also used to construct the Company’s Zika, RSV and HIV vaccine candidates.
Johnson & Johnson’s efforts to expedite development and production of a vaccine are enhanced by the existing COVID-19 vaccine collaborations between Janssen and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services. On March 13, 2020, a new collaboration was announced with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a preventive vaccine candidate for COVID-19.
More information: https://www.jnj.com/coronavirus